Mitochondrial superoxide (none)

Mitochondrial superoxide is a highly reactive free radical (O2•−) generated as a byproduct of oxidative phosphorylation in the mitochondrial electron transport chain, primarily at Complex I and Complex III. It plays dual roles in physiology and pathology: at low levels it contributes to normal cell signaling, but at high levels it induces oxidative stress, damages cellular components, and contributes to cell death. Mitochondrial superoxide is a major source of reactive oxygen species (ROS) in cells, and is implicated in diseases of aging, neurodegeneration, cardiovascular dysfunction, cancer, and inflammatory conditions. While mitochondria-targeted antioxidative approaches are an area of therapeutic interest, mitochondrial superoxide itself is not a druggable target in the classic sense (such as a receptor, enzyme, transporter, or protein); rather, it is a harmful molecule to be neutralized or its overproduction to be prevented. Thus, while drugs exist that interact with or modulate mitochondrial superoxide levels, mitochondrial superoxide itself is not a protein or established “target”, and is best classified as a reactive chemical species/biomarker rather than a canonical therapeutic target.

Other names

mitochondrial O2•−mitochondrial reactive oxygen species (mtROS)superoxide anion radical (within mitochondria)

Antioxidants/drugs may scavenge or neutralize mitochondrial superoxide (O2•−), convert it to hydrogen peroxide (H2O2) via SOD2, or prevent its formation by stabilizing electron transport complexes. Some drugs (e.g., Antimycin A) increase superoxide production by inhibiting mitochondrial Complex III. Mitochondria-targeted antioxidants aim to directly reduce mtO2•− levels and downstream oxidative damage.